Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Ultragenyx Pharmaceutical Inc.’s stock clocked out at $45.11, up 3.25% from its previous closing price of $43.69. In other words, the price has increased by $3.25 from its previous closing price. On the day, 0.84 million shares were traded. RARE stock price reached its highest trading level at $45.5788 during the session, while it also had its lowest trading level at $43.13.
Ratios:
To gain a deeper understanding of RARE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.61. In the meantime, Its Debt-to-Equity ratio is 3.39 whereas as Long-Term Debt/Eq ratio is at 3.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on April 22, 2024, initiated with a Outperform rating and assigned the stock a target price of $77.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 18 ’24 when Crombez Eric sold 142 shares for $44.10 per share. The transaction valued at 6,262 led to the insider holds 48,785 shares of the business.
Kassberg Thomas Richard sold 11,509 shares of RARE for $574,644 on Mar 11 ’24. The CBO & EVP now owns 252,823 shares after completing the transaction at $49.93 per share. On Mar 07 ’24, another insider, Fust Matthew K, who serves as the Director of the company, sold 12,195 shares for $50.88 each. As a result, the insider received 620,443 and left with 14,860 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3714163200 and an Enterprise Value of 3954773248. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.55 while its Price-to-Book (P/B) ratio in mrq is 13.48. Its current Enterprise Value per Revenue stands at 9.107 whereas that against EBITDA is -7.28.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $54.98, while it has fallen to a 52-week low of $31.52. The 50-Day Moving Average of the stock is -5.83%, while the 200-Day Moving Average is calculated to be 7.10%.
Shares Statistics:
It appears that RARE traded 693.74K shares on average per day over the past three months and 837800 shares per day over the past ten days. A total of 82.31M shares are outstanding, with a floating share count of 77.02M. Insiders hold about 6.45% of the company’s shares, while institutions hold 104.17% stake in the company. Shares short for RARE as of 1711584000 were 3918427 with a Short Ratio of 5.65, compared to 1709164800 on 3867566. Therefore, it implies a Short% of Shares Outstanding of 3918427 and a Short% of Float of 4.95.
